Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Non-cash Items (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Non-cash Items for 4 consecutive years, with $200000.0 as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 89.83% to $200000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $200000.0 through Dec 2025, down 89.83% year-over-year, with the annual reading at $200000.0 for FY2025, 89.83% down from the prior year.
  • Non-cash Items hit $200000.0 in Q4 2025 for Taysha Gene Therapies, down from $31.1 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $47.4 million in Q1 2022 to a low of $62000.0 in Q4 2022.
  • Historically, Non-cash Items has averaged $11.6 million across 4 years, with a median of $5.7 million in 2023.
  • Biggest five-year swings in Non-cash Items: skyrocketed 12723.53% in 2023 and later tumbled 92.65% in 2025.
  • Year by year, Non-cash Items stood at $62000.0 in 2022, then soared by 3061.29% to $2.0 million in 2023, then grew by 0.36% to $2.0 million in 2024, then crashed by 89.83% to $200000.0 in 2025.
  • Business Quant data shows Non-cash Items for TSHA at $200000.0 in Q4 2025, $31.1 million in Q3 2025, and $22.2 million in Q2 2025.